Literature DB >> 26358798

Anaplastic Thyroid Carcinoma, Version 2.2015.

Robert I Haddad, William M Lydiatt, Douglas W Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M Lamonica, Judith C McCaffrey, Jeffrey F Moley, Lee Parks, Christopher D Raeburn, John A Ridge, Matthew D Ringel, Randall P Scheri, Jatin P Shah, Robert C Smallridge, Cord Sturgeon, Thomas N Wang, Lori J Wirth, Karin G Hoffmann, Miranda Hughes.   

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Copyright © 2015 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26358798      PMCID： PMC4986600          DOI： 10.6004/jnccn.2015.0139

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  94 in total

1.  Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006.

Authors:  Briseis Aschebrook-Kilfoy; Mary H Ward; Mona M Sabra; Susan S Devesa
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

2.  Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy.

Authors:  E J Junor; J Paul; N S Reed
Journal:  Eur J Surg Oncol       Date:  1992-04       Impact factor: 4.424

Review 3.  State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83).

Authors:  V Grégoire; T R Mackie
Journal:  Cancer Radiother       Date:  2011-07-28       Impact factor: 1.018

4.  BRAF V600E inhibition in anaplastic thyroid cancer.

Authors:  Michael H Rosove; Parvin F Peddi; John A Glaspy
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

5.  New targeted therapies for anaplastic thyroid cancer.

Authors:  Alessandro Antonelli; Poupak Fallahi; Salvatore Ulisse; Silvia Martina Ferrari; Michele Minuto; Giovanna Saraceno; Francesca Santini; Valeria Mazzi; Massimo D'Armiento; Paolo Miccoli
Journal:  Anticancer Agents Med Chem       Date:  2012-01       Impact factor: 2.505

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy.

Authors:  Renaud De Crevoisier; Eric Baudin; Anne Bachelot; Sophie Leboulleux; Jean-Paul Travagli; Bernard Caillou; Martin Schlumberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-15       Impact factor: 7.038

8.  Prognosis and treatment of brain metastases in thyroid carcinoma.

Authors:  A C Chiu; E S Delpassand; S I Sherman
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

9.  Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Authors:  Panayiotis Savvides; Govardhanan Nagaiah; Pierre Lavertu; Pingfu Fu; John J Wright; Robert Chapman; Jay Wasman; Afshin Dowlati; Scot C Remick
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

10.  Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.

Authors:  Marcia S Brose; Christopher M Nutting; Steven I Sherman; Young Kee Shong; Johannes W A Smit; Gerhard Reike; John Chung; Joachim Kalmus; Christian Kappeler; Martin Schlumberger
Journal:  BMC Cancer       Date:  2011-08-11       Impact factor: 4.430
View more
  40 in total

1.  Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience.

Authors:  Emily Parkhurst; Elise Calonico; Sridevi Abboy
Journal:  J Genet Couns       Date:  2018-06-27       Impact factor: 2.537

2.  Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.

Authors:  Zorica Milošević; Jasna Banković; Jelena Dinić; Chrisiida Tsimplouli; Evangelia Sereti; Miodrag Dragoj; Verica Paunović; Zorka Milovanović; Marija Stepanović; Nikola Tanić; Kostantinos Dimas; Milica Pešić
Journal:  Cell Oncol (Dordr)       Date:  2018-05-22       Impact factor: 6.730

Review 3.  Tailored surgery according to molecular analysis in differentiated thyroid carcinomas.

Authors:  Paolo Miccoli; Gabriele Materazzi; Elisabetta Macerola; Sohail Bakkar
Journal:  Gland Surg       Date:  2018-08

4.  Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.

Authors:  Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins
Journal:  Head Neck       Date:  2019-12-16       Impact factor: 3.147

5.  LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.

Authors:  Xiao-Ming Wang; Yang Liu; Yu-Xia Fan; Zheng Liu; Qing-Ling Yuan; Meng Jia; Zu-Shi Geng; Ling Gu; Xiu-Bo Lu
Journal:  Cancer Biol Ther       Date:  2018-05-03       Impact factor: 4.742

6.  [Applicational value of 2017 ACR TI-RADS stratification in diagnosing thyroid nodules].

Authors:  P Fu; W Chen; L G Cui; H Y Ge; S M Wang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18

7.  The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

Authors:  Roy Lirov; Francis P Worden; Mark S Cohen
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

8.  Self-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivors.

Authors:  S C Roberts; S M Seav; T W McDade; S A Dominick; J R Gorman; B W Whitcomb; H I Su
Journal:  Hum Reprod       Date:  2016-05-11       Impact factor: 6.918

9.  Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.

Authors:  Teresa Di Desidero; Paola Orlandi; Daniela Gentile; Marta Banchi; Greta Alì; Claudia Kusmic; Paolo Armanetti; Ginelle J Cayme; Luca Menichetti; Gabriella Fontanini; Giulio Francia; Guido Bocci
Journal:  Pharmacol Res       Date:  2020-05-24       Impact factor: 7.658

10.  Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer.

Authors:  Woo Kyung Lee; Won Gu Kim; Laura Fozzatti; Sunmi Park; Li Zhao; Mark C Willingham; David Lonard; Bert W O'Malley; Sheue-Yann Cheng
Journal:  Endocr Relat Cancer       Date:  2020-04       Impact factor: 5.678
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.